Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Amarilis Perez

Neither a doctor nor a teaching hospital

Research payments

$452,474

23 payments

Through program year 2025, Amarilis Perez is reported as receiving $452,474 in research payments, across 23 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $169,398 4
2024 Research $40,138 6
2023 Research $161,662 7
2022 Research $81,240 5
2019 Research $36 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly Export S.A. Puerto Rico Branch $364,842 14 payments
  2. Eli Lilly and Company $87,632 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $135,923 3 payments
  2. A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $62,855 2 payments
  3. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $62,035 3 payments
  4. A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Two-Arm Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ly3361237 As A Treatment for Adults With at Least Moderately Active Systemic Lupus Erythematosus $47,324 2 payments
  5. A Master Protocol for A Randomized, Placebo-Controlled Clinical Trial of Multiple Interventions for the Treatment of Systemic Lupus Erythematosus $43,584 2 payments
  6. A Master Protocol for A Randomized Placebo-Controlled Clinical Trial of Multiple Interventions for the Treatment of Systemic Lupus Erythematosus $24,536 1 payment
  7. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (NKTR 358) in Adults With Systemic Lupus Erythematosus $19,028 1 payment
  8. A Randomized Active-Controlled Parallel-Group Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $18,525 1 payment
  9. A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $15,410 2 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ly3361237 As A Treatment for Adults With at Least Moderately Active Systemic Lupus Erythematosus $10,796 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record